We performed a combined retrospective analysis of 146 men with BRPC treated on phase-2 trials using one of four investigational drugs : lenalidomide ( n = 60 ) , marimastat ( n = 39 ) , ATN-224 ( n = 22 ) and imatinib ( n = 25 ) .